Press Release

REGENXBIO to Present at Upcoming Investor Conferences

ROCKVILLE, Md., Oct. 03, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will present at the following October investor conferences:

Chardan Inaugural Gene Therapy Conference
Date: Tuesday, October 10, 2017
Location: The Westin New York Grand Central Hotel
Fireside chat: Tuesday, October 10, 2017 at 9:30 a.m. ET
Panel: Gene Therapies: Pricing and Other Commercial Considerations; Tuesday, October 10, 2017 at 4:15 p.m. ET

Jefferies Gene Therapy Technology Investor Summit
Date: Thursday, October 12, 2017
Location: The Westin New York Grand Central Hotel
Fireside chat: Thursday, October 12, 2017 at 3:10 p.m. ET

A live webcast of each presentation can be accessed in the Investors section of REGENXBIO’s website at www.regenxbio.com. An archived replay of each webcast will be available on the same website for approximately 30 days following the presentation. In addition, REGENXBIO senior management will be holding one-on-one meetings at each of the conferences.

About REGENXBIO

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

CONTACT:

Investors
Natalie Wildenradt, 646-681-8192
natalie@argotpartners.com

Media
Adam Pawluk, 202-591-4063
apawluk@jpa.com

Primary Logo

REGENXBIO Inc.